Bioasis Technologies Inc. · OTC:BIOAF
Bioasis Technologies — Merger or Acquisition (December 2022)
30 slides from Bioasis Technologies's merger presentation, December 2022
Slide 1: Bioasis Shareholder Presentation December 2022
(NASDAQ:MTP | AIM:MTPH) (TSXV:BTI) Bioasis Shareholder Presentation December 2022 (pending NASDAQ:BDRX)
Slide 2: Disclaimer
Disclaimer The following presentation, including a hard copy of these slides, the information communicated during any delivery of the presentation and any question and answer session, and any document or material distributed at or in connection with the presentation (together, the “Presentation”), h
Slide 3: Risk Factors
Risk Factors Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in Midatech’s SEC filings and Bioasis’ filings with Canadian securities regulators. If any of the followin
Slide 4: Acquisition Overview
Acquisition Overview • Midatech Pharma plc (NASDAQ:MTP | AIM:MTPH) has conditionally agreed to the terms of an acquisition of Bioasis Technologies Inc. (TSXV:BTI) to create a multi-asset rare and orphan disease drug company that will be renamed Biodexa Pharmaceuticals. (NASDAQ:MTP | AIM:MTPH) (TSXV:
Slide 5: Combined Company Overview
Combined Company Overview • Focused on therapeutics for rare and orphan drug Partners Utilizing xB3 Platform diseases in oncology and neurodegenerative disorders. • Clinical pipeline is enabled by a suite of delivery and therapeutic platforms. • Epidermal Growth Factor Therapeutics Aimed at treating
Slide 6: Clinical Pipeline
Clinical Pipeline • The clinical pipeline of the combined company will include the following programs: Product Preclinical Phase I Phase II Upcoming Catalysts DIPG (Diffuse Intrinsic Pontine • H1 2023 Phase II IND filing MTX110 Glioma) Initial Focus (to be renamed BDX110) Panobinostat • H1 2023 Firs
Slide 7: Strategic Partners
Strategic Partners Utilizing Midatech’s and Bioasis’ Delivery Platform Partner Overview Platform(s) Indication(s) Proceeds Received Potential Future Proceeds • Four undisclosed lysosomal • USD$3.0M • Up to USD$138M xB3 disorders • Royalty on net 2020 revenue of USD$2.3B sales • Undisclosed • USD$1.0
Slide 8: Anticipated Catalysts
Anticipated Catalysts BDX101 BDX102 EGF Platform BDX103 BDX101 BDX101 Commence GMP Orphan Drug Conference presentations Orphan Drug Optic Neuritis Optic Neuritis trial manufacture Designation filings GBS European Academy of Designation filing associated with MS FPFV Neurology and Neurology & CIDP IN
Slide 9: BDX110
biodexa BDX110
Slide 10: BDX110 Direct Delivery of Panobinostat
BDX110 Direct Delivery of Panobinostat • BDX110 • Direct delivery treatment of Panobinostat SynchroMed II Pump • Re-fillable pump implanted in abdomen • Delivers drug intra-tumorally to target location • Bypasses blood-brain barrier • Opportunity to deliver maximal therapeutic dose • Minimises poten
Slide 11: Panobinostat
Panobinostat A promising therapy for DIPG (Brain Cancer in Children) • In a screen of 83 drugs panobinostat was among the most effective agents1 • Convection-enhanced delivery (CED) to directly infuse panobinostat into the pons of a DIPG orthotopic xenograft model showed: • A marked effect on the ra
Slide 12: Diffuse Intrinsic Pontine Glioma (DIPG)
BDX110 Diffuse Intrinsic Pontine Glioma (DIPG) • Significant unmet medical need • About 300 children diagnosed in the US pa1, over 1,100 worldwide2 • Median survival of approximately 10 months • Resection not possible, no effective treatment3 • Phase I programme: • ‘201 study (UCSF) n=7 showed: • We
Slide 13: DIPG – Clinical Data
BDX110 Diffuse Intrinsic Pontine Glioma (DIPG) – Clinical Data The median overall survival (OS) for cohort was 26.1 months (95% confidence interval) Median survival based on a cohort of 316 cases was 10.0 months1 1. Jansen et al, 2015. Neuro-Oncology 17(1):160-166 13
Slide 14: Glioblastoma (GBM)
BDX110 Glioblastoma (GBM) • Problem: TumVolume (mm3) • Many drug failures due to poor BBB penetration • Potential Solution: • BDX110 is delivered intra-tumorally at high doses via CED, by- passing the BBB • Compelling mechanism and preclinical evidence of efficacy in Figure 1. Tumour volume data fro
Slide 15: Glioblastoma (GBM) Background
BDX110 Glioblastoma (GBM) Background • Most common and aggressive form of brain cancer in adults. • Survival with standard of care treatment ranges from approximately 13 to 30 months depending on MGMT methylation. • Standard of care: resection, radiation, limited drug options • Near 100% recurrence
Slide 16: BDX101 BDX102 BDX103
biodexa BDX101 BDX102 BDX103
Slide 17: Epidermal Growth Factor (EGF) Platform
Epidermal Growth Factor (EGF) Platform Novel Treatment Approach For Neurodegenerative Disorders • Epidermal Growth Factor (“EGF”) • Neurodegenerative Disorders • EGF Treatment • EGF levels are deficient in • Stimulates myelin • Protein that stimulates cell growth neurodegenerative disorders regenera
Slide 18: EGF Decreases Inflammation and Prevents Demyelination
EGF Decreases Inflammation and Prevents Demyelination • MOG-induced EAE (a model of MS) mouse brain demonstrated absence of any demyelination when treated with EGF (Luxol fast blue stained sections of spinal cord). • The staining with LFB shows the formation of demyelination plaques occurred in the
Slide 19: EGF Effectively Treats Neuroinflammation in EAN
EGF Effectively Treats Neuroinflammation in EAN • EAN is the animal model of CIDP and Guillain-Barre Syndrome. Nicoletti et al J Neuroimmunol. 2019 19
Slide 20: BDX101 Optic Neuritis
BDX101 Optic Neuritis • BDX101 is being developed for optic neuritis associated with multiple sclerosis to reduce demyelinating inflammation of the optic nerve. PREVALENCE/INCIDENCE MARKET • Treatment Options: Optic neuritis treatment market • IV Steroids US Annual Incidence estimated at 6.4 per US$
Slide 21: Proposed Phase 2 Study Design
Proposed Phase 2 Study Design BDX101 – Optic Neuritis • A double-blind Phase 2 POC study of EGF 1-48 in MS-related optic neuritis is planned following completion of the merger. BDX101 Phase 2 POC1-5 Population 40 Design: 2 groups receiving either EGF 1-48 subcutaneously on alternate days daily f
Slide 22: BDX102 Guillain-Barré Syndrome (GBS)
BDX102 Guillain-Barré Syndrome (GBS) • BDX102 is indicated for Guillain-Barré Syndrome, a rare and progressive disease characterized by inflammation of the nerves (polyneuritis) causing muscle weakness, sometimes progressing to complete paralysis. PREVALENCE/INCIDENCE MARKET 3000 to 6000 150,095 Glo
Slide 23: BDX103 CIDP
BDX103 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) • BDX103 is indicated for CIDP, a rare neurological disorder in which there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) of the nerve fibers. PREVALENCE/IN
Slide 24: xB3 Platform
biodexa xB? Platform
Slide 25: xB3 Platform
xB3 Platform • xB3 platform utilises the Partners Utilizing xB3 Platform low-density lipoprotein-related protein 1 (LRP1) receptor • Carries payloads across the BBB via a process of endocytosis and transcytosis • Applicable to variety of actives including monoclonal antibodies, enzymes and oligonucl
Slide 26: xB3 Platform vs. Other Blood-Brain Barrier Technologies
xB3 Platform vs. Other Blood-Brain Barrier Technologies • The xB3 Platform Technology delivers therapeutics across the blood-brain barrier to treat orphan and rare genetic diseases and has been demonstrated to outperform competing blood-brain barrier technologies. Features xB3 Platform Denali Genent
Slide 27: Q-Sphera Technology Platform
Q-Sphera Technology Platform
Slide 28: Q-Sphera Technology Platform
Q-Sphera Technology Platform • Q-Sphera is a polymer microsphere 3D Pharmaceutical Printing Process microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. • Industrial printing technology reinvented 30 - 6
Slide 29: Proposed Board of Directors
Proposed Board of Directors Stephen Parker Stephen Stamp Deborah Rathjen Chairman CEO/CFO Non-executive Director Dr. Parker is Chairman of Sareum Mr. Stamp has held senior positions in a Dr Rathjen is currently Executive Chair Holdings plc (AIM: SAR) and Drishti number of significant healthcare of B
Slide 30: Investment Summary
Investment Summary • Company focused on therapeutics for rare and orphan Partners Utilizing xB3 Platform drug diseases in oncology and neurodegenerative disorders. • Clinical pipeline is enabled by a suite of delivery and therapeutic platforms. • Epidermal Growth Factor Therapeutics Aimed at treatin
Bioasis Technologies — Merger or Acquisition (December 2022) on 6ix